Archiv
Archiv anzeigen:
bis


Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.


Ramucirumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Petrylak DP et al. Lancet 2017 Sep 12, Bellmunt J. Lancet 2017 Sep 12

Adding the IgG1 monoclonal antibody ramucirumab to docetaxel improved progression-free survival at 5-month follow-up.


ALK Rearrangements in Malignant Peritoneal Mesothelioma

Anne S. Tsao, MD reviewing Hung YP et al. JAMA Oncol 2017 Sep 14

Novel genetic aberrations were found in 3% of tumors.


Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes

Henry Mark Kuerer, MD, PhD, FACS reviewing Giuliano AE et al. JAMA 2017 Sep 12, Livingston EH and Li HC. JAMA 2017 Sep 12

Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.


First-Line Radiotherapy for Colorectal Cancer Liver Metastases

David H. Ilson, MD, PhD reviewing Wasan HS et al. Lancet Oncol 2017 Sep

Adding selective internal radiotherapy to chemotherapy failed to improve survival and increased risk for adverse events.


Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

David H. Ilson, MD, PhD reviewing Alderson D et al. Lancet Oncol 2017 Sep

More intense preoperative chemotherapy fails to improve survival.


Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

David H. Ilson, MD, PhD reviewing Overman MJ et al. Lancet Oncol 2017 Sep

The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.


Bleeding Risk with Thrombocytopenia

David Green, MD, PhD reviewing Uhl L et al. Blood 2017 Sep 7

More evidence that in thrombocytopenic patients, platelet count is an imprecise predictor of bleeding.


Does Cutting Dietary Fat Affect Breast Cancer Outcomes?

Andrew M. Kaunitz, MD reviewing Chlebowski RT et al. J Clin Oncol 2017 Sep 1

Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.


An Effective New Option for Refractory Hodgkin Lymphoma

Michael E. Williams, MD, ScM reviewing Martínez C et al. J Clin Oncol 2017 Aug 28

Outcomes with haploidentical stem-cell transplantation plus cyclophosphamide were similar to those with matched related or unrelated donor transplantation.


Archiv
Seite von 59
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.